Jane Street’s Palvella Therapeutics PVLA Stock Holding History

Jane Street’s Portfolio PVLA Stock Details PVLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$798K	Buy	6,400 +3,800	+146%	+$396K	﹤0.01%	6982
2025 Q4	$272K	Buy	+2,600	New	+$222K	﹤0.01%	9060
2021 Q4	–	Sell	-265	Closed	-$110K	–	10934
2021 Q3	$110K	Sell	265 -489	-65%	-$170K	﹤0.01%	9247
2021 Q2	$231K	Buy	+754	New	+$165K	﹤0.01%	8596

Other funds holding PVLA

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Jane Street's PVLA Position: Q4 2025 in Review

Jane Street sold out of Palvella Therapeutics (PVLA) in Q4 2025, closing a stake of 10,017 shares — an estimated $855K sold.

Jane Street first reported a position in PVLA in Q2 2019 and held it in 9 quarters. The position peaked at $628K in Q3 2025. 140 funds tracked by Wall St. Rank hold PVLA as of Q4 2025.

Jane Street reported no remaining Palvella Therapeutics position as of Q4 2025 after selling out during the quarter.
Jane Street sold 10,017 Palvella Therapeutics shares in Q4 2025, an estimated $855K.
Jane Street first reported a position in Palvella Therapeutics in Q2 2019 and held it in 9 quarters.
Jane Street's Palvella Therapeutics position peaked at $628K in Q3 2025.
140 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q4 2025.

Based on Jane Street's 13F filing for Q4 2025, filed 12 Feb 2026.